ReNeuron's hRPC stem cells improve vision in first cohort of retinitis pigmentosa patients

ReNeuron Group plc (LSE:RENE) said a single subretinal implantation of its hRPC stem cells led significant improvements in visual acuity in three patients with retinitis pigmentosa

Read the full 262 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE